Your browser doesn't support javascript.
Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco, Giorgia Teresa; Manzo, Valentino; Ferrara, Anne Lise; Perrella, Alessandro; Di Battista, Mariaelena; Salvatore, Simona; Graziano, Daniela; Viola, Assunta; Amato, Gerardino; Moreggia, Ornella; Di Giulio Cesare, Daniele; Barbato, Stefano; Servillo, Giovanna; Longo, Katia; Di Giovanni, Mario; Scarpati, Barbara; Muggianu, Simona Maria; Longo, Giuseppe; Russo, Giuseppe; Andreone, Vincenzo; De Rosa, Veronica.
  • Maniscalco GT; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy; Multiple Sclerosis Center, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: gtmaniscalco@libero.it.
  • Manzo V; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: valentino.manzo@aocardarelli.it.
  • Ferrara AL; Institute of Endocrinology and Experimental Oncology (IEOS-CNR), Via S. Pansini 5, 80131, Naples, Italy; Department of Translational Medical Science and Center for Basic and Clinical Immunology Research (CISI), University of Naples "Federico II", Via S. Pansini 5, Naples 80131, Italy. Electronic add
  • Perrella A; Infectious Disease of Healthcare Direction, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: alessandro.perrella@aocardarelli.it.
  • Di Battista M; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy; Multiple Sclerosis Center, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: mariaelena.dibattista@aocardarelli.it.
  • Salvatore S; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy; Multiple Sclerosis Center, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: simona.salvatore@aocardarelli.it.
  • Graziano D; Unit of Transfusional Medicine, SIMT, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: daniela.graziano@aocardarelli.it.
  • Viola A; Molecular Biology Laboratory, Hematology and Transplantation CSE, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: assunta.viola@aocardarelli.it.
  • Amato G; Clinical Pathology and Microbiology Laboratory "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: gerardino.amato@aocardarelli.it.
  • Moreggia O; Multiple Sclerosis Center, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: ornellamoreggia@gmail.com.
  • Di Giulio Cesare D; Multiple Sclerosis Center, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: daniel.dgc@alice.com.
  • Barbato S; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: stefano.barbato@aocardarelli.it.
  • Servillo G; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: giovanna.servillo@aocardarelli.it.
  • Longo K; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: katia.longo@aocardarelli.it.
  • Di Giovanni M; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: mario.digiovanni@aocardarelli.it.
  • Scarpati B; Unit of Transfusional Medicine, SIMT, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: barbara.scarpati@aocardarelli.it.
  • Muggianu SM; Molecular Biology Laboratory, Hematology and Transplantation CSE, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: simonamaria.muggianu@aocardarelli.it.
  • Longo G; General Direction "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: direzione.generale@aocardarelli.it.
  • Russo G; Infectious Disease of Healthcare Direction, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: direzione.sanitaria@aocardarelli.it.
  • Andreone V; Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. Electronic address: vincenzo.andreone@aocardarelli.it.
  • De Rosa V; Institute of Endocrinology and Experimental Oncology (IEOS-CNR), Via S. Pansini 5, 80131, Naples, Italy. Electronic address: veronica.derosa@cnr.it.
Mult Scler Relat Disord ; 58: 103455, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1586960
ABSTRACT

BACKGROUND:

Several concerns exist on the immunogenicity of SARS-CoV-2 vaccines in multiple sclerosis (MS) subjects due to their immunomodulating disease modifying therapies (DMTs). Here we report a comparison of the humoral response to BNT162b2-mRNA coronavirus (COVID)-19 vaccine and the immunological phenotype in a cohort of 125 MS subjects undergoing different DMTs, with no history of SARS-CoV-2 infection.

METHODS:

We collected serum and blood samples at the first day of vaccine (T0) and 21 days after the second vaccine dose (T1) from 125 MS subjects, undergoing eight different DMTs. Sera were tested using the Elecsys anti-SARS-CoV-2-IgG assay for the detection of IgG antibodies to SARS-CoV-2 spike protein. The anti-spike IgG titres from MS subjects were compared with 24 age- and sex-matched healthy controls (HC). Percentage and absolute number of B and T lymphocytes were evaluated by cytofluorimetric analysis in the same study cohort.

RESULTS:

When compared with SARS-CoV-2 IgG levels in HC (n = 24, median 1089 (IQR 652.5-1625) U/mL), we observed an increased secretion of SARS-CoV-2 IgG in interferon-beta 1a (IFN)-treated MS subjects (n = 22, median 1916 (IQR 1024-2879) U/mL) and an impaired humoral response in MS subjects undergoing cladribine (CLAD) (n = 10, median 396.9 (IQR 37.52-790.9) U/mL), fingolimod (FTY) (n = 19, median 7.9 (IQR 4.8-147.6) U/mL) and ocrelizumab (OCRE) (n = 15, median 0.67 (IQR 0.4-5.9) U/mL) treatment. Moreover, analysis of geometric mean titre ratio (GMTR) between different DMT's groups of MS subjects revealed that, when compared with IFN-treated MS subjects, intrinsic antibody production was impaired in teriflunomide (TERI)-, natalizumab (NAT)-, CLAD-, FTY- and OCRE-, while preserved in DMF- and GA-treated MS subjects.

CONCLUSION:

Humoral response to BNT162b2-mRNA-vaccine was increased in IFN-treated MS subjects while clearly blunted in those under CLAD, FTY and OCRE treatment. This suggests that the DMTs could have a key role in the protection from SARS-CoV-2 related disease and complication in MS subjects, underlying a novel aspect that should be considered in the selection of the most appropriate therapy under COVID-19 pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article